Organigram Global announced plans to acquire Sanity Group, a German cannabis company, in an all-cash transaction valued at up to €227.2 million. The deal comprises €113.4 million in upfront consideration with an additional €113.8 million in earnout payments contingent on the achievement of specified milestones. The acquisition represents a significant expansion of Organigram's European operations and positions the company to compete more effectively in the continent's growing cannabis market.
The transaction will be funded through a combination of Organigram's existing cash reserves, a newly secured credit facility, and a €47.8 million strategic investment from British American Tobacco. The tobacco giant's involvement underscores growing institutional interest in the cannabis sector and provides Organigram with additional financial flexibility to complete the acquisition and support integration efforts.
Organigram's shares advanced 7.09 percent in premarket trading following the announcement. The acquisition aligns with the company's stated objective to establish a robust global cannabis platform with diversified geographic revenue streams. Sanity Group operates licensed cultivation and distribution operations in Germany, providing Organigram with immediate access to established European infrastructure and regulatory relationships.